Similar articles for PMID: 14722202

Year	Number of Results
1998	1
1999	1
2000	3
2001	4
2002	7
2003	2
2004	9
2005	15
2006	11
2007	13
2008	11
2009	15
2010	10
2011	9
2012	6
2013	2
2014	5
2015	3
2016	1
2017	3
2018	1
2019	3
2021	3
2023	2
2024	0

1

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.

Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumali H, Voudouris K, Boumpas DT. Sidiropoulos P, et al. Ann Rheum Dis. 2004 Feb;63(2):144-8. doi: 10.1136/ard.2003.015933. Ann Rheum Dis. 2004. PMID: 14722202 Free PMC article. Clinical Trial.

2

Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.

Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA; FARR study group. Allaart CF, et al. Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-77-82. Clin Exp Rheumatol. 2006. PMID: 17083767 Clinical Trial.

3

[Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis].

Wiland P, Głowska A, Chlebicki A, Szechiński J. Wiland P, et al. Pol Arch Med Wewn. 2002 Nov;108(5):1055-63. Pol Arch Med Wewn. 2002. PMID: 12685246 Clinical Trial. Polish.

4

Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.

Fleischmann R, Goldman JA, Leirisalo-Repo M, Zanetakis E, El-Kadi H, Kellner H, Bolce R, DeHoratius R, Wang J, Decktor D. Fleischmann R, et al. Curr Med Res Opin. 2014 Nov;30(11):2139-49. doi: 10.1185/03007995.2014.942416. Epub 2014 Jul 30. Curr Med Res Opin. 2014. PMID: 25050591 Clinical Trial.

5

Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions.

Edrees AF, Misra SN, Abdou NI. Edrees AF, et al. Clin Exp Rheumatol. 2005 Jul-Aug;23(4):469-74. Clin Exp Rheumatol. 2005. PMID: 16095114 Clinical Trial.

6

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.

Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE; ATTRACT Study Group. Smolen JS, et al. Arthritis Rheum. 2005 Apr;52(4):1020-30. doi: 10.1002/art.20982. Arthritis Rheum. 2005. PMID: 15818697 Free article. Clinical Trial.

7

Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.

Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF; PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial. Shergy WJ, et al. J Rheumatol. 2002 Apr;29(4):667-77. J Rheumatol. 2002. PMID: 11950005 Clinical Trial.

8

Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.

Flendrie M, Creemers MC, van Riel PL. Flendrie M, et al. Rheumatology (Oxford). 2007 Jan;46(1):146-9. doi: 10.1093/rheumatology/kel173. Epub 2006 Jun 16. Rheumatology (Oxford). 2007. PMID: 16782732 Clinical Trial.

9

Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.

van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH. van den Bemt BJ, et al. Ann Rheum Dis. 2008 Dec;67(12):1697-701. doi: 10.1136/ard.2007.083683. Epub 2008 Jan 31. Ann Rheum Dis. 2008. PMID: 18245109 Clinical Trial.

10

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Lipsky PE, et al. N Engl J Med. 2000 Nov 30;343(22):1594-602. doi: 10.1056/NEJM200011303432202. N Engl J Med. 2000. PMID: 11096166 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

121 results

Results by year